Akari Therapeutics
AKTX
12 hedge funds and large institutions have $2.27M invested in Akari Therapeutics in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
42% less capital invested
Capital invested by funds: $3.9M → $2.27M (-$1.63M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFW
Omnia Family Wealth
Aventura,
Florida
|
+$101K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$52.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$48K |
| 4 |
Renaissance Technologies
New York
|
+$36.8K |
| 5 |
HF
HRT Financial
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UAS
United Asset Strategies
Garden City,
New York
|
-$765K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OFW
1
Omnia Family Wealth
Aventura,
Florida
| $808K | +$101K | +63 | +12% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $782K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $262K | +$36.8K | +23 | +14% |
|
|
HP
4
Hikari Power
Tokyo,
Japan
| $155K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $90K | +$48K | +30 | +86% |
|
6
Geode Capital Management
Boston,
Massachusetts
| $52K | – | – | – |
|
|
7
HighTower Advisors
Chicago,
Illinois
| $45K | +$52.8K | +33 | New |
|
|
HF
8
HRT Financial
New York
| $37K | +$11.2K | +7 | +35% |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $21K | – | – | – |
|
10
Morgan Stanley
New York
| $11K | +$1.6K | +1 | +14% |
|
11
Bank of America
Charlotte,
North Carolina
| $5K | – | – | – |
|
|
TC
12
Truvestments Capital
Sarasota,
Florida
| $3K | – | – | – |
|
|
UAS
13
United Asset Strategies
Garden City,
New York
| – | -$765K | -362 | Closed |
|
AKTX Hedge Fund Activity: Q2 2021 in Review
12 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2021, worth a combined $2.27M — down 42% from $3.9M a quarter earlier.
Fund positioning in AKTX was balanced in Q2 2021: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 0 trimmed.
The largest buyer was Omnia Family Wealth, adding an estimated $101K. The largest seller was United Asset Strategies, exiting entirely with an estimated $765K sold.
- 12 institutional investors held Akari Therapeutics (AKTX) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $2.27M of Akari Therapeutics stock for Q2 2021, down 42% quarter-over-quarter.
- 1 fund opened new Akari Therapeutics positions in Q2 2021 and 1 closed out, a net change of 0 holders.
- The largest Akari Therapeutics buyer in Q2 2021 was Omnia Family Wealth, an estimated $101K added.
- The largest Akari Therapeutics seller in Q2 2021 was United Asset Strategies, an estimated $765K sold.
Based on aggregated 13F filings for Q2 2021.